The Brief

Researchers at INSERM Strasbourg have mapped the calcium signaling mechanism by which circulating tumor cells commandeer blood vessel walls to escape into surrounding tissue — the critical step in metastasis that accounts for the vast majority of cancer deaths. The team demonstrated that blocking the calcium channels involved, using an existing hypertension drug, reduced tumor cell extravasation in animal models.

The Report

A research team led by Jacky Goetz and Naël Osmani at INSERM’s Tumor Biomechanics laboratory in Strasbourg has detailed the precise molecular sequence by which circulating tumor cells exit the bloodstream and seed secondary cancers in distant organs. The work, published in iScience and built upon in a January 2026 Nature Materials study, addresses what remains the primary driver of cancer mortality: metastatic spread, which contributes to an estimated 67–90% of cancer deaths depending on tumor type.

Using high-resolution intravital imaging in zebrafish embryos, the team observed that when a tumor cell arrests in a blood vessel — typically at branching points where flow slows — it triggers a spike in calcium ion concentration in the endothelial cells lining the vessel wall. That calcium influx sets off a chain reaction: the endothelial cells reorganise their actin cytoskeleton, form protrusions around the tumor cell, and effectively push it through the vessel wall into surrounding tissue. The blood vessel, in other words, does not passively allow the cancer cell to escape. It is manipulated into assisting.

The researchers identified three specific ion channels mediating the process — P2X4, TRP, and Piezo1 mechano-gated calcium channels — along with voltage-dependent L-type calcium channels as regulators of extravasation. Lead author Marina Peralta and colleagues then tested nifedipine, an L-type calcium channel blocker already prescribed for hypertension and angina, and found it decreased calcium entry, reduced actin reorganisation, and diminished tumor cell extravasation in their zebrafish models.

The companion Nature Materials study, conducted with collaborators at the Max Planck Institute for the Science of Light in Erlangen, added a further dimension: tumor cell viscosity, not elasticity, determines whether circulating cells enter small vessels, arrest, and extravasate. “Our work identifies cell viscosity as a key mechanical parameter that controls multiple steps of the metastatic process,” said co-author Salvatore Girardo. The finding introduces a paradox — mechanical traits that help tumor cells leave the bloodstream may conflict with traits supporting their later growth at distant sites.

The Goetz laboratory has spent over a decade building toward these results. Earlier work validated zebrafish models against a cohort of 100 patients with brain metastases and established that tumor-derived extracellular vesicles — lipid droplets roughly 100 nanometres across — precede metastatic cells to “prepare the ground” in target organs. The team also identified adhesion proteins CD44 and α5β1 integrin as mechanisms enabling tumor cells to anchor against blood flow.

Nifedipine’s therapeutic potential carries a significant caveat. Separate studies using human breast cancer cell lines found the same drug increased transmigration of certain cancer cells through endothelial barriers, suggesting the effect may be cancer-type-specific and model-dependent. Clinical application of calcium channel blockers for anti-metastatic therapy will require careful drug selection. Human trials of the calcium-blocking approach have not yet begun.

The Angle

What the Strasbourg team has produced over the past decade is not a single discovery but something more structurally significant: a mechanical map of cancer’s most lethal transition. The metastatic cascade has been described in outline for over a century — Stephen Paget’s seed-and-soil hypothesis dates to 1889. What has been missing is the engineering-level detail of how tumor cells actually breach the vessel wall. The calcium mechanism fills that gap with specificity that is, for the first time, actionable.

The therapeutic implication is worth stating precisely. Fewer than 0.1% of tumor cells that enter circulation successfully metastasise. The bottleneck is extravasation — the step this research targets. If that bottleneck can be narrowed further, even modestly, the arithmetic of metastatic cancer changes. Not by attacking the tumor itself, but by cutting the supply line between the primary site and everywhere else. The fact that calcium channel blockers already exist, are already prescribed for other conditions, and are already understood pharmacologically means the distance between this finding and a clinical trial is shorter than the distance between most basic research and anything a patient might benefit from.

The nifedipine contradiction — effective in zebrafish, potentially counterproductive in certain human breast cancer lines — is not a setback so much as a specification. It narrows the problem from “can we block this mechanism” to “which blocker, for which cancer, at which dosage.” That is the kind of question drug development is built to answer. The mechanism itself holds.

Metastasis kills nine in ten cancer patients by exploiting a vulnerability in the body’s own infrastructure — and for the first time, the engineering diagram of that exploitation is detailed enough to suggest where to cut the wire.